Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Mylan Pharmaceuticals, Mylan's US subsidiary, has launched one of the first generic versions of Abbott's Trilipix Capsule in the US.
Subscribe to our email newsletter
Known as Fenofibric Acid Delayed-release Capsules, 45mg and 135mg is indicated for patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their low-density lipoprotein cholesterol goal.
New generic product is used as an adjunct to diet in combination with a statin to lessen triglyceride and enhance high-density lipoprotein cholesterol.
The US Food and Drug Administration has approved the product’s abbreviated new drug application.
The sales of Fenofibric Acid Delayed-release Capsules, 45mg and 135mg, were around $553.6m for the 12 months ending on 31 March 2013 in the US, according to IMS Health data.